{
    "2018-10-18": [
        [
            {
                "time": "2018-10-31",
                "original_text": "Pfizer’s Growth Rate and Estimates",
                "features": {
                    "keywords": [
                        "Growth",
                        "Rate",
                        "Estimates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-31",
                "original_text": "Top-Ranked Healthcare ETFs for Long-Term Investors",
                "features": {
                    "keywords": [
                        "Healthcare",
                        "ETFs",
                        "Long-Term",
                        "Investors"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-31",
                "original_text": "What Are Pfizer’s Revenue Drivers?",
                "features": {
                    "keywords": [
                        "Revenue",
                        "Drivers"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-01",
                "original_text": "Novartis Missed Revenue Estimates in Q3 2018",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Missed",
                        "Revenue",
                        "Estimates",
                        "Q3",
                        "2018"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-02",
                "original_text": "Will Pfizer hit $50? Is Cleveland-Cliffs a safe bet ahead...",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "$50",
                        "Cleveland-Cliffs",
                        "safe",
                        "bet"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "materials"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-03",
                "original_text": "Pfizer’s Market Cap and Shareholding Pattern",
                "features": {
                    "keywords": [
                        "Market",
                        "Cap",
                        "Shareholding",
                        "Pattern"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-04",
                "original_text": "Analyzing Pfizer’s Stock Performance in October",
                "features": {
                    "keywords": [
                        "Stock",
                        "Performance",
                        "October"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "Dow stocks Pfizer and UnitedHealth could be safety plays amid market volatility",
                "features": {
                    "keywords": [
                        "Dow",
                        "stocks",
                        "Pfizer",
                        "UnitedHealth",
                        "safety",
                        "plays",
                        "market",
                        "volatility"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "insurance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "Pfizer Confirms to Cut Workforce by 2%",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Confirms",
                        "Cut",
                        "Workforce",
                        "2%"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-07",
                "original_text": "5 Things You Should Know About Johnson & Johnson's Third Quarter",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Third",
                        "Quarter"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-08",
                "original_text": "Is Sangamo Therapeutics Inc. a Buy?",
                "features": {
                    "keywords": [
                        "Sangamo",
                        "Therapeutics",
                        "Inc.",
                        "Buy"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-09",
                "original_text": "See what the IHS Markit Score report has to say about Pfizer Inc.",
                "features": {
                    "keywords": [
                        "IHS",
                        "Markit",
                        "Score",
                        "report",
                        "Pfizer",
                        "Inc."
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-10",
                "original_text": "Merck, Pfizer combo treatment meets main goals of kidney cancer trial",
                "features": {
                    "keywords": [
                        "Merck",
                        "Pfizer",
                        "combo",
                        "treatment",
                        "meets",
                        "main",
                        "goals",
                        "kidney",
                        "cancer",
                        "trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-11",
                "original_text": "Pfizer Layoffs: Company to Offer Early Retirement Deals Ahead of Cuts",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Layoffs",
                        "Early",
                        "Retirement",
                        "Deals",
                        "Cuts"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-12",
                "original_text": "Merck Says Pivotal Phase 3 KEYNOTE-426 Trial Meets Both Primary Endpoints",
                "features": {
                    "keywords": [
                        "Merck",
                        "Pivotal",
                        "Phase",
                        "3",
                        "KEYNOTE-426",
                        "Trial",
                        "Meets",
                        "Primary",
                        "Endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}